Individual recurrence intervals after anti-VEGF therapy for age-related macular degeneration
To assess the time interval to recurrent choroidal neovascular membrane (CNV) activity in eyes with neovascular age-related macular degeneration (AMD) after intravitreal anti-VEGF therapy.
Data from all patients who received intravitreal ranibizumab injections for neovascular AMD at the University of Cologne prior to February 2009 were retrospectively reviewed. Patients were treated on a pro re nata (PRN) basis and eyes with active CNV received three consecutive monthly injections. Recurrence of CNV activity was defined as recurrence of intra- or subretinal fluid on optical coherence tomography (OCT) or leakage on fluorescein angiography (FA) after initial resolution of fluid and leakage following anti-VEGF therapy. All eyes showing at least two documented recurrences of CNV activity during follow-up were included in this analysis. Recurrence intervals were calculated and were deemed to be regular or periodical if the difference between recurrence interval times was less than 50 days.
Twenty-nine eyes of 28 patients met the inclusion criteria. Two to six recurrences were detected per case (mean 2.8 ± 1.1 recurrences). Recurrence intervals ranged from 41 days to 523 days (mean 5.5 ± 3.4 months, median 4.5 months). Twenty-two eyes (76%) showed at least two periodical recurrence intervals. In 12 eyes (41%), all recurrences occurred at regular intervals (2-4 recurrences, mean 2.3 ± 0.6 recurrences). Seven eyes (24%) showed irregular recurrence intervals (2-3 recurrences, mean 2.1 ± 0.4 recurrences). All 11 eyes with a classic CNV lesion component showed at least two periodical recurrence intervals. Eyes with occult CNV lesions showed periodical recurrence intervals in 11 out of 18 cases (61%).
Preliminary data indicate that periodical recurrences of CNV activity may be seen in eyes with neovascular AMD undergoing anti-VEGF therapy. Knowledge of individual recurrence interval times may allow for the development of an individualized treatment plan and prophylactic therapy.
- Augood C, Fletcher A, Bentham G, Chakravarthy U, de Jong PT, Rahu M, Seland J, Soubrane G, Tomazzoli L, Topouzis F, Vioque J, Young I (2004) Methods for a population-based study of the prevalence of and risk factors for age-related maculopathy and macular degeneration in elderly European populations: the EUREYE study. Ophthalmic Epidemiol 11:117–129 CrossRef
- Bressler NM (2004) Age-related macular degeneration is the leading cause of blindness. JAMA 291:1900–1901 CrossRef
- Friedman DS, O'Colmain BJ, Munoz B, Tomany SC, McCarty C, de Jong PT, Nemesure B, Mitchell P, Kempen J (2004) Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 122:564–572 CrossRef
- Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, Mariotti SP (2004) Global data on visual impairment in the year 2002. Bull World Health Organ 82:844–851
- Ferris FL 3rd, Fine SL, Hyman L (1984) Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 102:1640–1642
- Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432–1444 CrossRef
- Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431 CrossRef
- Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, Shams N (2008) Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 145:239–248 CrossRef
- Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW Jr, Esquiabro M (2007) An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143:566–583 CrossRef
- Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, Davis JL, Flynn HW Jr, Esquiabro M (2009) A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 148(43–58):e41
- Bashshur ZF, Haddad ZA, Schakal A, Jaafar RF, Saab M, Noureddin BN (2008) Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol 145:249–256 CrossRef
- Bashshur ZF, Haddad ZA, Schakal AR, Jaafar RF, Saad A, Noureddin BN (2009) Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study. Am J Ophthalmol 148(59–65):e51
- Meyer CH, Eter N, Holz FG (2008) Ranibizumab in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Interim results from the sustain trial [abstract]. Invest Ophthalmol Vis Sci: E-abstract 273
- Gupta OP, Shienbaum G, Patel AH, Fecarotta C, Kaiser RS, Regillo CD (2010) A treat-and-extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology. Jun 29 (epub ahead of print)
- Brown DM, Regillo CD (2007) Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol 144:627–637 CrossRef
- Spaide R (2007) Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol 143:679–680 CrossRef
- Engelbert M, Zweifel SA, Freund KB (2009) "Treat and extend" dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation. Retina 29:1424–1431 CrossRef
- Dadgostar H, Ventura AA, Chung JY, Sharma S, Kaiser PK (2009) Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration. Ophthalmology 116:1740-1747
- Pauleikhoff D (2005) Neovascular age-related macular degeneration: Natural history and treatment outcomes. Retina 25:1065–1084 CrossRef
- Individual recurrence intervals after anti-VEGF therapy for age-related macular degeneration
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Graefe's Archive for Clinical and Experimental Ophthalmology
Volume 249, Issue 5 , pp 645-652
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Neovascular age-related macular degeneration
- Anti-VEGF therapy
- Industry Sectors
- Author Affiliations
- 1. Department of Vitreoretinal Surgery, Center for Ophthalmology, University of Cologne, Kerpener Strasse 62, 50924, Cologne, Germany
- 2. Doheny Retina Institute, Doheny Eye Institute, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA